Detalhe da pesquisa
1.
Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo.
Mov Disord
; 35(2): 245-255, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31840869
2.
Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease.
Neurobiol Dis
; 96: 335-345, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27425888
3.
Bone morphogenetic protein-inducer tilorone identified by high-throughput screening is antifibrotic in vivo.
Am J Respir Cell Mol Biol
; 48(4): 448-55, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23258233
4.
Persephin signaling through GFRalpha1: the potential for the treatment of Parkinson's disease.
Mol Cell Neurosci
; 44(3): 223-32, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20350599
5.
Comparison of liquid chromatography-mass spectrometry and direct infusion microchip electrospray ionization mass spectrometry in global metabolomics of cell samples.
Eur J Pharm Sci
; 138: 104991, 2019 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31404622
6.
GDNF family receptor complexes are emerging drug targets.
Trends Pharmacol Sci
; 28(2): 68-74, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17218019
7.
Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus infection in vitro and differentially affect cellular signaling, transcription and metabolism.
Antiviral Res
; 139: 117-128, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28049006
8.
A Novel Small Molecule GDNF Receptor RET Agonist, BT13, Promotes Neurite Growth from Sensory Neurons in Vitro and Attenuates Experimental Neuropathy in the Rat.
Front Pharmacol
; 8: 365, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28680400
9.
The first cysteine-rich domain of the receptor GFRalpha1 stabilizes the binding of GDNF.
Biochem J
; 387(Pt 3): 817-24, 2005 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15610063
10.
Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.
Cancer Discov
; 3(12): 1416-29, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24056683
11.
Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin.
J Cell Biol
; 192(1): 153-69, 2011 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-21200028
12.
Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons.
Exp Neurol
; 219(2): 499-506, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19615368
13.
Sensory neurons from N-syndecan-deficient mice are defective in survival.
Neuroreport
; 19(14): 1397-400, 2008 Sep 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-18766019
14.
Novel computational models for predicting dopamine interactions.
Exp Neurol
; 211(1): 150-71, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18331731
15.
The structure of the glial cell line-derived neurotrophic factor-coreceptor complex: insights into RET signaling and heparin binding.
J Biol Chem
; 283(50): 35164-72, 2008 Dec 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-18845535
16.
The structure of GFRalpha1 domain 3 reveals new insights into GDNF binding and RET activation.
EMBO J
; 23(7): 1452-62, 2004 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-15044950